Gen Digital Inc. (GEN)
NASDAQ: GEN · Real-Time Price · USD
28.79
-0.70 (-2.37%)
At close: Aug 1, 2025, 4:00 PM
28.94
+0.15 (0.52%)
After-hours: Aug 1, 2025, 7:50 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $33.6, which forecasts a 16.71% increase in the stock price over the next year. The lowest target is $25 and the highest is $46.
Price Target: $33.60 (+16.71%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $46 | Strong Buy | Initiates | $46 | +59.78% | Jul 14, 2025 |
| Barclays | Barclays | Hold Maintains $30 → $32 | Hold | Maintains | $30 → $32 | +11.15% | Jul 14, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $35 | Buy | Initiates | $35 | +21.57% | Jul 1, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $28 → $30 | Hold | Maintains | $28 → $30 | +4.20% | May 7, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $27 → $25 | Hold | Maintains | $27 → $25 | -13.16% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
4.79B
from 3.94B
Increased by 21.65%
Revenue Next Year
5.03B
from 4.79B
Increased by 5.16%
EPS This Year
2.53
from 1.03
Increased by 145.39%
EPS Next Year
2.82
from 2.53
Increased by 11.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.1B | 5.4B | 5.6B | ||
| Avg | 4.8B | 5.0B | 5.3B | ||
| Low | 4.5B | 4.7B | 4.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.6% | 12.2% | 11.8% | ||
| Avg | 21.7% | 5.2% | 5.6% | ||
| Low | 13.5% | -2.8% | -2.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.65 | 3.09 | 3.53 | ||
| Avg | 2.53 | 2.82 | 3.12 | ||
| Low | 2.43 | 2.62 | 2.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 156.9% | 22.1% | 25.3% | ||
| Avg | 145.4% | 11.4% | 10.8% | ||
| Low | 136.0% | 3.5% | -1.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.